

Valeant Pharmaceuticals International, Inc.  
Form 8-K  
March 10, 2017

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): March 10, 2017 (March 9, 2017)**

**Valeant Pharmaceuticals International, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

<b>British Columbia, Canada</b> (State or Other Jurisdiction of Incorporation or Organization)	<b>001-14956</b> (Commission File Number)	<b>98-0448205</b> (I.R.S. Employer Identification Number)
--	--	---

**2150 St. Elzéar Blvd. West  
Laval, Quebec  
Canada H7L 4A8**

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 8-K

(Address of Principal Executive Offices)(Zip Code)

**514-744-6792**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

**Pricing of Notes Offering**

On March 10, 2017, Valeant Pharmaceuticals International, Inc. (the “Company”) issued a press release announcing that on March 9, 2017 it had priced its offering of \$1.25 billion aggregate principal amount of 6.50% senior secured notes due 2022 and \$2 billion aggregate principal amount of 7.00% senior secured notes due 2024. The aggregate offering size of \$3.25 billion reflects an increase of \$750 million from the previously announced offering size.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release announcing the pricing of the notes offering, dated March 10, 2017.

2

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

By: /s/ Paul S. Herendeen

Name: Paul S. Herendeen

Title: Executive Vice President and Chief Financial Officer

Date: March 10, 2017

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release announcing the pricing of the notes offering, dated March 10, 2017.